A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

Researcher Information

Amy Fulton, Ph.D.
Professor of Pathology

Department:
Department of Pathology

UMGCC Research Program:
Hormone Responsive Cancers Program

Education/Training:
College Degree: B.A., University of Kansas
Medical Degree: Ph.D., University of Wisconsin
Fellowship: University of British Columbia

Contact Information:

Mailing Address: Dept. of Pathology
10 S. Pine St.
Baltimore, MD 21201
Email: afulton@umaryland.edu
Phone: 410-706-6479
Fax: 410-706-8414

Research Interests:
My laboratory is interested in identifying the mechanisms by which breast cancers grow and metastasize and in developing therapeutic strategies against breast cancer. Our studies show that overexpression of cyclooxygenase-2 is an indicator of aggressive disease and preclinical studies indicate that cyclooxygenase inhibitors may limit tumor growth and spread. We are investigating a new strategy to inhibit COX-2 signaling by antagonizing prostaglandin E (EP) receptors. We have shown that antagonizing the EP4 receptor inhibits metastasis. Current studies examine mechanisms by which cyclooxygenase inhibitors enhance anti-tumor immunity. We are also investigating how cytokines and chemokines and their specific receptors modify tumor behavior. We have identified therapeutic activities for several cytokines. We have also identified a pharmacologic antagonist of one chemokine receptor and shown that this agent inhibits tumor metastasis.

Publications:
Kundu, N. and Fulton, A.M. Selective Cox-1 and Cox-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Research 62:2343-2346, 2002.

Dorsey, R., Kundu, N., Yang, Q., Tannenbaum, C.S., Sun, H., Hamilton, T.A. and Fulton, A.M. Immunotherapy with IL-10 depends on the CXC chemokines IP-10 and MIG. Cancer Research 62:2606-2610, 2002.

Kundu, N., Smyth, M., Samsel, L. and Fulton, A.M. Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle in breast cancer cells. Breast Cancer Res. Treatment 76:57-64, 2002.

Ma, X., Yang, Q., Wilson, K.T., Kundu, N., Meltzer, S.J. and Fulton, A.M. Promoter methylation regulates cyclooxygenase (COX-2) expression in breast cancer. Breast Cancer Research 6:R316-321, 2004.

Selaru, F.M., Yin, J., Olaru, A., Mori, Y., Xu, Y., Epstein, S., Sato, F., Deacu, E., Wang, S., Sterian, A., Fulton, A.M., Abraham, J.M., Shibata, D., Baquet, C., Stass, S.A. and Meltzer, S.J. An unsupervised approach to identify molecular phenotypic components influencing breast cancer features. Cancer Research 64:1584-1588, 2004.

Walser, T.C. and Fulton, A.M. The role of chemokines in the biology and therapy of breast cancer. Breast Dis. 20:137-143, 2004.

Kundu, N., Walser, T.C., Ma, X. and Fulton, A.M. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol. Immunother. 54:981-987, 2005.

Hahn, T., Alvarez, I., Kobie, J.J., Ramanathauram, L., Dial, S., Fulton, A.M., Besselsen, D., Walker, E., and Akporiaye, E.T. dietary celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int. J. Cancer 118:2220-2231, 2006.

Ma, X., Kundu, N., Rifat, S., Walser, T. and Fulton, A.M> Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res. 66:2923-2927, 2006.

Walser, T.C., Rifat, S., Ma, X., Kundu, N., Ward, C., Goloubeva, O., Johnson, M.G., Medina, J.C., Collins, T.L. and Fulton, A.M. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res. (in press), 2006.